When it comes to colon cancer checks, options exist

Key points
- For people who have had a negative colonoscopy, less-invasive screening options may work just fine for follow-up cancer tests, a new analysis suggests.
- "No one screening test is right for everyone," lead researcher Amy Knudsen, from the Institute for Technology Assessment at Massachusetts General Hospital in Boston, told Reuters Health in an email.
- The findings, which are based on a mathematical model, showed life expectancy varied by only a few days between people who continued getting colonoscopies every ten years and those who chose annual fecal blood tests and other less-invasive alternatives.
- "The best test for you depends on your risk, your preferences, and which screening approach you are willing and able to adhere to, since no screening is effective unless it's done," she added.
For people who have had a negative colonoscopy, less-invasive screening options may work just fine for follow-up cancer tests, a new analysis suggests.
"No one screening test is right for everyone," lead researcher Amy Knudsen, from the Institute for Technology Assessment at Massachusetts General Hospital in Boston, told Reuters Health in an email.
The findings, which are based on a mathematical model, showed life expectancy varied by only a few days between people who continued getting colonoscopies every ten years and those who chose annual fecal blood tests and other less-invasive alternatives.
"The best test for you depends on your risk, your preferences, and which screening approach you are willing and able to adhere to, since no screening is effective unless it's done," she added.
"Patients should talk with their doctors to decide which test is best for them."
Knudsen's team fed colon cancer screening and survival data into a National Cancer Institute (NCI) model, starting with hypothetical study participants that had a negative colonoscopy at age 50.
The researchers found that with no further screening, 31 out of every 1,000 people would be diagnosed with colon cancer during their lives and 12 would die from it. For people who continued having colonoscopies every ten years, that would fall to eight colon cancer diagnoses and two deaths per 1,000 people.
With annual fecal tests starting at age 60, Knudsen and her colleagues calculated that 11 to 13 out of every 1,000 people would get colon cancer, and three or four would die.
And with the last screening method, known as computed tomographic colonography, or CTC, nine people would be diagnosed with cancer and three would die if the tests were done every five years. Like colonoscopy, CTC requires bowel preparation, but otherwise is not as invasive.
The less-invasive screening methods would each cause about half as many complications as colonoscopy - affecting one percent of patients versus two percent, according to findings published Monday in the Annals of Internal Medicine. Those complications include bleeding and colon perforations.
"All of these methods will work if your ultimate goal is to reduce deaths from colon cancer," said gastroenterologist Dr. David Weinberg from Fox Chase Cancer Center in Philadelphia, who wrote an editorial accompanying the study.
PAYING A LOT MORE
According to the NCI, about 143,000 people are expected to be diagnosed with colon or rectal cancer in 2012, and close to 52,000 will die of the disease.
Weinberg said one of the advantages of colonoscopy is that it finds pre-cancerous polyps that can be removed before they turn into cancer.
Fecal blood tests, on the other hand, typically catch very early cancers, so more patients screened that way will get cancer and need treatment, although they'll have a good prognosis.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNew presurgery combination therapy may improve outcomes for women with triple-negative breast cancer
The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly…
17 December 2013
NewsDeep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy
New research from University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University examined how changes in the genetic composition of breast…
13 December 2013
NewsBiomarker linked to aggressive breast cancers, poor outcomes in African-Americans
Among African-American women with breast cancer, increased levels of the protein HSET were associated with worse breast cancer outcomes, according to results presented here at the Sixth AACR Conference on the Science of…





